Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
CAR immune cells: design principles, resistance and the next generation
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
DR Wang, XL Wu, YL Sun - Signal transduction and targeted therapy, 2022 - nature.com
Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …
malignant cells but also an altered immune response. The inhibition and reprogramming of …
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Despite impressive progress, more than 50% of patients treated with CD19-targeting
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
[HTML][HTML] Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19
chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of …
chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of …
Scalable manufacturing of CAR T cells for cancer immunotherapy
As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T
cell therapies for hematologic malignancies. With the current transition of CAR T cell …
cell therapies for hematologic malignancies. With the current transition of CAR T cell …
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells
Chimeric antigen receptor (CAR) T-cell toxicities resembling hemophagocytic
lymphohistiocytosis (HLH) occur in a subset of patients with cytokine release syndrome …
lymphohistiocytosis (HLH) occur in a subset of patients with cytokine release syndrome …
Born to survive: how cancer cells resist CAR T cell therapy
Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with
chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This …
chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This …
Engineering-enhanced CAR T cells for improved cancer therapy
MC Milone, J Xu, SJ Chen, MKA Collins, J Zhou… - Nature cancer, 2021 - nature.com
Chimeric antigen receptor (CAR) T cell therapies have evolved from a research tool to a
concept-shifting therapy with impressive responses in B cell malignancies. This Review …
concept-shifting therapy with impressive responses in B cell malignancies. This Review …
Recent advances and challenges in cancer immunotherapy
C Peterson, N Denlinger, Y Yang - Cancers, 2022 - mdpi.com
Simple Summary Immunotherapy helps a person's immune system to target tumor cells.
Recent advances in cancer immunotherapy, including immune checkpoint inhibition …
Recent advances in cancer immunotherapy, including immune checkpoint inhibition …